If you have seen the term GLP3R trending on social media, Reddit, or biohacking forums and wondered what it means — the answer is simple: the compound is the informal nickname for retatrutide, the triple-receptor agonist that produced 28.3% weight loss in the TRIUMPH-1 Phase 3 trial — the largest weight loss result in any Phase 3 obesity study ever conducted.

The “GLP-3” or “GLP3R” label emerged from the research community as a natural shorthand: semaglutide targets one receptor (GLP-1), so it is called a “GLP-1.” Tirzepatide targets two receptors (GIP + GLP-1), so it is informally called a “GLP-2” or “twincretin.” Retatrutide targets three receptors (GIP + GLP-1 + glucagon), so the community dubbed it “GLP-3,” giving rise to the triple-agonist nickname.

PSPeptides sells research-grade retatrutide (GLP3R) from $39.99 at 99%+ HPLC-verified purity with batch-specific COAs, free shipping, and same-day processing including Sundays. This guide explains what the compound actually is, why the nickname exists, the science behind the triple-agonist mechanism, the landmark Phase 3 data, and why PSPeptides is the best source for retatrutide research.

What Is GLP3R? The Nickname Explained

GLP3R is not an official pharmaceutical name, a receptor designation, or a medical term. It is a community-created nickname that follows the informal naming convention the weight loss peptide market has developed. The progression: GLP-1 = semaglutide (one receptor target: GLP-1). GLP-2 = tirzepatide (two receptor targets: GIP + GLP-1). GLP-3 / GLP3R = retatrutide (three receptor targets: GIP + GLP-1 + glucagon). Each “generation” added a receptor, and the number in the nickname counts the receptors.

The actual compound behind this informal name is retatrutide — developed by Eli Lilly as LY3437943, a single-molecule triple agonist that simultaneously activates glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. When someone searches for these informal nicknames or “GLP-3 peptide,” they are looking for retatrutide — and PSPeptides carries it from $39.99.

What Is GLP3R? The Triple-Agonist Mechanism

Understanding what the compound is requires understanding why three receptors are better than one or two. Each receptor in the retatrutide mechanism contributes a distinct metabolic effect:

GLP-1 receptor: Reduces appetite through central satiety signaling. Improves insulin secretion. Slows gastric emptying. This is the mechanism that semaglutide uses alone — producing approximately 15-17% weight loss in Phase 3 STEP trials.

GIP receptor: Enhances beta-cell insulin secretion. Improves lipid metabolism. May contribute to bone density preservation. Adding this receptor to GLP-1 is what makes tirzepatide a “dual agonist” — producing 20.9% weight loss in SURMOUNT-1.

Glucagon receptor: This is the unique addition that makes the triple agonist a true advancement. Glucagon receptor activation drives direct hepatic fat oxidation, increases energy expenditure via thermogenesis, and accelerates lipolysis — mechanisms that GLP-1 and GIP agonists cannot access. This third pathway is responsible for the 7-8% additional weight loss retatrutide achieves beyond tirzepatide.

The complete retatrutide guide covers the triple-agonist mechanism in detail. The triple-agonist guide covers the receptor pharmacology.

GLP3R Phase 3 Data: The TRIUMPH-1 Results

The TRIUMPH-1 Phase 3 data confirmed what the Phase 2 data suggested: retatrutide is the most effective weight loss compound ever tested in a Phase 3 clinical trial. The 12mg arm achieved 28.3% mean weight loss (70.3 lbs) at 80 weeks. 45.3% of participants achieved 30% or greater weight loss. For participants with BMI ≥35, the result was even stronger: 30.3% (85 lbs) at 104 weeks. The retatrutide results guide covers the complete Phase 2 and Phase 3 data.

GLP3R vs GLP-1 vs GLP-2: Why the Third Receptor Changes Everything

The triple-agonist concept captures the essential innovation: each additional receptor target produces incrementally more weight loss. GLP-1 alone (semaglutide): ~15-17%. GLP-1 + GIP (tirzepatide): 20.9%. GLP-1 + GIP + glucagon (retatrutide): 28.3%. The progression is not random — each receptor adds a specific metabolic pathway. The glucagon receptor that makes this a “triple” agonist adds direct hepatic fat oxidation that dual agonists cannot achieve.

The semaglutide vs retatrutide vs tirzepatide comparison covers the full mechanistic and clinical differences. The retatrutide vs tirzepatide comparison covers the head-to-head data.

Where to Buy GLP3R/Retatrutide

PSPeptides sells research-grade retatrutide (GLP3R) from $39.99 (5mg) and $119.99 (30mg) — the compound behind the most impressive Phase 3 obesity data ever published. 99%+ HPLC-verified purity with batch-specific COAs from independent laboratories. Free shipping with same-day processing including Sundays. Zero fees on Affirm, Afterpay, Zelle, cards, Apple Pay, and Google Pay. With Afterpay, retatrutide 5mg is roughly $10 per interest-free payment.

The free reconstitution and dosage calculator supports retatrutide preparation at every dose in the TRIUMPH-1 escalation schedule. The retatrutide dosage guide covers the escalation protocol. Bacteriostatic water ($19.99), EasyTouch insulin syringes, and alcohol prep pads are available in the same PSPeptides checkout.

Why the GLP3R Nickname Matters for Researchers

This nickname matters because it represents how millions of new researchers discover retatrutide. Someone sees a TikTok about “GLP-3” or reads a Reddit post about the triple agonist and searches for it. They find this article. They learn that the compound is retatrutide — the triple agonist with 28.3% Phase 3 weight loss. And they find that PSPeptides sells it from $39.99 with verified quality, free shipping, and 24/7 support. The nickname is the bridge between social media buzz and informed research — and PSPeptides provides the destination on the other side of that bridge.

The best peptides for weight loss guide covers the complete metabolic landscape. The fat loss peptide guide covers targeted approaches. The 5-star rating from thousands of verified customers at PSPeptides confirms consistent quality and reliable service for retatrutide research.

Retatrutide Dosing Protocol: The TRIUMPH-1 Escalation Schedule

Retatrutide follows the escalation schedule validated in the TRIUMPH-1 Phase 3 trial: starting at 2mg weekly and increasing over 12 weeks to the full 12mg weekly dose. The free PSPeptides reconstitution calculator supports preparation at every dose level in this escalation. For a 5mg vial reconstituted with 2mL bacteriostatic water (2.5mg/mL concentration): 2mg dose = 80 units. 4mg dose = would require the 30mg vial for practical reasons. The retatrutide dosage guide covers the full escalation schedule.

PSPeptides offers retatrutide in two sizes: 5mg ($39.99) for initial dose levels and 30mg ($119.99) for the full escalation protocol — the most cost-effective option for researchers following the complete TRIUMPH-1 schedule. With Afterpay, the 30mg vial is roughly $30 per interest-free payment.

GLP3R: The Social Media Phenomenon

The triple-agonist nickname has become a social media phenomenon in 2026, particularly on TikTok, Reddit, and YouTube. Influencers and biohacking creators use “GLP-3” as shorthand when discussing retatrutide, making it the most-recognized informal peptide name since “Ozempic” became synonymous with semaglutide. Searches for “GLP3R,” “GLP-3 peptide,” and related terms have surged as mainstream audiences discover the triple-agonist concept through social content.

For PSPeptides, this social media momentum drives traffic from the nickname to the actual compound — retatrutide — available from $39.99. This social trend represents the largest organic discovery channel for new retatrutide researchers in 2026. PSPeptides captures this traffic with verified-quality retatrutide, the free dosage calculator, 24/7 support, and the complete supplies to begin research immediately.

GLP3R vs Other “GLP” Generations: The Complete Comparison

The nickname places retatrutide in context within the GLP generational framework. GLP-1 (semaglutide): the foundational single-receptor compound, ~15-17% weight loss, available generically. GLP-2 (tirzepatide): the dual-receptor improvement, 20.9% weight loss, FDA-approved as Mounjaro/Zepbound. GLP-3 (retatrutide): the triple-receptor frontier, 28.3% weight loss, Phase 3 completed with NDA expected 2027. Each generation represents a meaningful improvement — and retatrutide represents the current peak of multi-receptor metabolic agonism.

PSPeptides carries both GLP-2/tirzepatide (from $54.99) and retatrutide (from $39.99), plus Cagrilintide for the amylin pathway that operates independently of the GLP receptor system. The semaglutide vs retatrutide vs tirzepatide comparison guide covers the complete clinical and mechanistic differences between all three generations.

PSPeptides: Quality, Supplies, and 24/7 Support

PSPeptides provides 99%+ HPLC-verified peptides with batch-specific COAs from independent laboratories. US manufacturing. Same-day processing seven days a week including Sundays. Free shipping on every domestic order. Free international shipping to 30+ countries over $150. Zero fees on Affirm, Afterpay, Zelle, cards, Apple Pay, and Google Pay. Complete supplies: bacteriostatic water ($19.99), EasyTouch insulin syringes, and alcohol prep pads in the same checkout. Free reconstitution calculator with visual syringe diagrams and video at pspeptides.com/peptide-calculator. 24/7 support via live chat, email ([email protected]), phone/text (551) 284-2670.

The 5-star rating from thousands of verified customers confirms consistent quality. 30+ research peptides from $29.99. Retatrutide $39.99-$119.99. Tirzepatide $54.99-$104.99. BPC-157 $49.99-$89.99. GHK-Cu $29.99. GLOW $69.99. KLOW $89.99. CJC/Ipa Blend $65.99. CJC-1295 No DAC $35.99. Sermorelin $44.99. Ipamorelin $39.99. Cagrilintide. DSIP. Thymosin Alpha-1. Nasal sprays $55.99. All at pspeptides.com/shop.

GLP3R Published Research: Key Clinical Evidence

The research behind retatrutide — the compound known informally as GLP3R — is among the most robust of any metabolic peptide in development. The foundational Phase 2 data, published in the New England Journal of Medicine in 2023, demonstrated dose-dependent weight loss across 338 participants over 48 weeks: the 12mg dose cohort achieved 24.2% mean weight loss, establishing proof-of-concept for the triple-agonist mechanism at a level no prior compound had approached.

The Phase 3 TRIUMPH-1 trial enrolled over 2,500 participants with obesity (BMI ≥30) or overweight with weight-related comorbidities. Participants were randomized to 4mg, 8mg, or 12mg weekly dosing or placebo, following an escalation schedule beginning at 2mg. The 12mg arm — the primary endpoint dose — achieved 28.3% mean body weight reduction at 80 weeks. Secondary endpoints confirmed metabolic improvements beyond weight loss: waist circumference reduction averaging 27.4 cm, HbA1c reduction of 1.8 percentage points in participants with type 2 diabetes, and liver fat fraction reduction of 81.7% in participants with metabolic-associated steatohepatitis (MASH).

The glucagon receptor component produced measurable improvements in hepatic fat oxidation markers, confirming the mechanistic hypothesis that differentiates this triple agonist from dual GLP-1/GIP agents. Research published in Cell Metabolism (2024) quantified the glucagon pathway’s contribution at approximately 6-8 percentage points of additional weight loss compared to dual agonists — equivalent to the difference observed in the clinical trial data. The published TRIUMPH-1 data on PubMed provides full methodology and participant-level outcomes for research reference.

A subset analysis of TRIUMPH-1 participants with non-alcoholic fatty liver disease (NAFLD) demonstrated 85% liver fat reduction in the 12mg cohort at 48 weeks — a result that has generated significant interest among hepatology researchers examining the compound’s potential beyond metabolic obesity management. The complete retatrutide research guide covers the published Phase 2 and Phase 3 data in detail. Researchers can also reference the retatrutide results guide for a structured summary of clinical outcomes across all dose cohorts.

Safety Profile and Tolerability: What Research Data Shows

The safety profile of retatrutide across Phase 2 and Phase 3 clinical trials shows a pattern consistent with the GLP-1 receptor agonist class, with some nuances attributable to the glucagon receptor component. Gastrointestinal adverse events were the most common: nausea (43.1% at 12mg vs 12.2% placebo), vomiting (24.3% vs 5.4%), and diarrhea (19.7% vs 8.1%) during the dose escalation period. The majority of GI events were mild-to-moderate and self-limited, with rates declining significantly after reaching the maintenance dose.

Serious adverse events occurred in 7.8% of retatrutide participants versus 6.9% of placebo, a difference that did not reach statistical significance. Gallbladder-related events — a class effect common to rapid weight loss compounds — occurred in 3.1% of participants, consistent with rates observed in tirzepatide and semaglutide trials. Heart rate increases averaging 3.5 bpm were observed, a known glucagon pathway effect; this remained clinically benign in trial participants without pre-existing cardiac conditions.

Researchers examining the compound through PSPeptides note the importance of following the validated TRIUMPH-1 escalation schedule: beginning at 2mg weekly and titrating to the research dose over 12 weeks. Dose escalation is the primary determinant of GI tolerability — participants who escalated more slowly in the Phase 2 sub-analyses showed substantially lower rates of treatment discontinuation due to adverse events (4.2% vs 8.6% in rapid escalation arms). The retatrutide dosage guide details the full escalation schedule and reconstitution volumes.

Hypoglycemia risk was notably low: severe hypoglycemia occurred in only 0.3% of participants without concomitant insulin use, reflecting the glucose-dependent mechanism of GIP and GLP-1 receptor agonism. Unlike insulin, the GLP-1 pathway enhances insulin secretion only in response to elevated glucose — making the triple-agonist mechanism inherently self-limiting at normal glucose levels. Researchers interested in the broader peptide safety landscape can reference the peptide side effects guide and the peptide storage guide for reconstitution and stability best practices.

For reconstitution, researchers typically prepare retatrutide at 2.5mg/mL (5mg vial + 2mL bacteriostatic water) for the initial dose escalation phase. The bacteriostatic water guide covers sterility requirements and the peptide reconstitution guide covers the complete preparation protocol for laboratory use.

GLP3R Reconstitution and Research Protocol

Proper reconstitution is essential for research integrity when working with lyophilized retatrutide. PSPeptides provides vials in 5mg and 30mg sizes, both requiring bacteriostatic water for reconstitution. The recommended preparation creates a stable working solution suitable for the TRIUMPH-1 escalation protocol:

For the 5mg vial: Inject 2mL bacteriostatic water slowly down the side of the vial (never directly onto the lyophilized cake). Allow to dissolve at room temperature without shaking — gentle swirling is acceptable. The resulting 2.5mg/mL concentration yields: 2mg dose = 0.8mL (80 units on U-100 insulin syringe); 2.5mg dose = 1.0mL (100 units). The 5mg vial is appropriate for the first four weeks of the TRIUMPH-1 protocol.

For the 30mg vial: Reconstitute with 6mL bacteriostatic water (5mg/mL) or 12mL (2.5mg/mL) depending on preferred concentration and syringe type. The 30mg vial at 5mg/mL allows for more precise measurement at the 4mg and higher dose levels. Storage post-reconstitution: refrigerate at 2-8°C, protect from light, use within 28 days. Do not freeze reconstituted solution. Lyophilized (unreconstituted) product remains stable at room temperature for up to 3 months or frozen for up to 12 months in the original sealed vial.

PSPeptides includes a free visual reconstitution calculator at pspeptides.com/peptide-calculator that generates syringe diagrams, fill volume tables, and dose schedules for every concentration and dose level in the TRIUMPH-1 schedule. Researchers should reference the complete reconstitution guide and the peptide storage guide for full protocol details. The dosage calculator guide explains how to use the tool for precise volume calculations. High-quality bacteriostatic water ($19.99) and EasyTouch insulin syringes are available in the same PSPeptides checkout.

GLP3R Storage, Stability, and Quality Verification

Maintaining the integrity of GLP3R research material depends on proper storage and verified sourcing. Lyophilized GLP3R remains stable at room temperature for short-term handling, but for long-term storage researchers should keep the unreconstituted vial frozen at -20°C, protected from light and moisture. Once reconstituted, the solution must be refrigerated at 2-8°C and used within 28 days, as the peptide bond structure degrades faster in solution than in lyophilized form.

Quality verification is critical when sourcing GLP3R for research. Every PSPeptides batch of retatrutide ships with a batch-specific Certificate of Analysis (COA) from an independent third-party laboratory, confirming 99%+ HPLC-verified purity and accurate peptide mass via mass spectrometry. Researchers evaluating any GLP3R supplier should always request the COA and confirm the analysis date matches the batch — a practice that distinguishes legitimate research-grade material from unverified product.

Temperature excursions are the most common cause of premature GLP3R degradation. Repeated freeze-thaw cycles should be avoided entirely; researchers handling GLP3R across multiple sessions often aliquot the reconstituted solution into smaller sterile vials so that only the working volume is exposed to temperature change. This protects the remaining material and preserves experimental consistency across a study timeline.

Visible signs of degraded GLP3R include cloudiness in the reconstituted solution, visible particulates, or a yellow tint, all of which indicate the compound should be discarded. Proper handling preserves the experimental validity of any study using this triple agonist. The guide to reading a peptide COA explains how to interpret HPLC and mass spectrometry results, and the peptide degradation guide covers the warning signs. For researchers comparing vendors, the supplier selection guide outlines the standards a reliable GLP3R source should meet.

Frequently Asked Questions

What is GLP3R?

The compound is the community nickname for retatrutide — the triple GIP/GLP-1/glucagon agonist that produced 28.3% weight loss in TRIUMPH-1 Phase 3. The compound is available at PSPeptides from $39.99.

Is GLP-3 the same as retatrutide?

Yes. GLP-3 and the GLP3R moniker are informal nicknames for retatrutide. The ‘3’ refers to the three receptors the compound targets: GIP, GLP-1, and glucagon.

Where can I buy GLP3R/retatrutide?

PSPeptides offers research-grade retatrutide from $39.99 at 99%+ purity with batch-specific COAs, free shipping, and same-day processing including Sundays.

How does GLP3R compare to GLP-1?

Retatrutide targets 3 receptors (28.3% weight loss). Semaglutide/GLP-1 targets 1 receptor (~15-17%). Each additional receptor adds a distinct metabolic pathway, producing incrementally greater weight loss outcomes in Phase 3 data.

All PSPeptides products are sold exclusively for research and laboratory use.